Welcome to our dedicated page for Adc Therapeutics Sa SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, drug-development milestones, and detailed R&D spending make ADC Therapeutics鈥� SEC documents some of the most technical in biotech. If you have ever searched "ADCT SEC filings explained simply" or wondered where to locate an "ADCT quarterly earnings report 10-Q filing" that actually highlights pipeline progress, you know the challenge.
Stock Titan solves it. Our AI parses every ADCT annual report 10-K, 10-Q, and 8-K the moment it hits EDGAR, then delivers plain-English summaries of cash runway, trial readouts, and collaboration terms鈥攏o biotech PhD required. Need "ADCT Form 4 insider transactions real-time" or alerts on "ADCT executive stock transactions Form 4" before markets react? We stream them instantly and add clear context. You can also compare compensation details through the "ADCT proxy statement executive compensation" section, while our earnings report filing analysis flags changes in R&D intensity quarter over quarter.
Whether you track "ADCT 8-K material events explained" for regulatory updates, want an "ADCT insider trading Form 4 transactions" history to gauge management conviction, or simply prefer an "ADCT annual report 10-K simplified" view that surfaces key risk factors, every disclosure lives here with AI-powered highlights, trend graphs, and exportable data. Understanding ADCT SEC documents with AI means spending minutes, not hours, to spot the information that moves oncology-focused valuations.
Sono-Tek Corporation (NASDAQ: SOTK) filed its Form 10-Q for the fiscal 2026 first quarter ended 31 May 2025. Net sales inched up 2% year-over-year to $5.13 million, driven largely by a repeat high-ASP order in the Alternative/Clean Energy market. A richer product mix and minimal distributor discounts lifted gross margin 310 bps to 51.9%, pushing gross profit up 9% to $2.67 million.
Operating expenses declined 2% to $2.18 million, mainly from lower R&D and selling costs, offset by higher G&A and stock-based compensation. Operating income more than doubled to $0.48 million, and net income rose 47% to $0.48 million ($0.03 per diluted share). Interest and dividend income remained stable at $0.14 million, while a small $0.02 million unrealized securities loss slightly trimmed pre-tax income.
Liquidity & Capital: Cash, cash equivalents and marketable securities totaled $10.9 million (down $1.1 million from year-end) with no debt. Operating cash flow swung to an outflow of $0.92 million, reflecting higher receivables (+$0.75 million), inventory build (+$0.37 million) and income-tax payments. Working capital improved to $13.9 million. The company maintained a $1.5 million unused revolving credit facility (aside from $0.106 million for LC collateral).
Backlog & Concentration: Combined equipment and service backlog declined 14% sequentially to $7.48 million. One customer represented 57% of quarterly sales and 68% of accounts receivable, highlighting concentration risk; management noted revised but collectible payment terms for this account.
Segment & Geographic trends:
- Integrated Coating Systems surged 309% to $3.05 million, now 59% of revenue.
- Multi-Axis Coating Systems fell 75% to $0.68 million on lower clean-energy R&D spending.
- Alt-Energy/Clean market revenue grew 42% to $3.25 million (63% of total).
- U.S./Canada sales jumped 15% to $3.54 million, now 69% of revenue; EMEA dropped 28%.
Capital allocation: Under a $2 million repurchase program, SOTK bought 21,335 shares for $79,479 during the quarter, leaving ~$1.9 million available.
Outlook comments (MD&A) emphasise continued focus on high-value, full-system solutions, expansion of global test labs, and variability in quarterly order flow tied to large machine sales. Management reiterated strong R&D, zero debt and sufficient liquidity to fund growth initiatives.
Kineta, LLC (successor by merger to Kineta, Inc.) has filed Post-Effective Amendment No. 1 to nine Form S-8 registration statements to deregister all unsold shares that had been reserved for issuance under multiple legacy equity compensation and employee stock purchase plans of Proteostasis Therapeutics, Yumanity Therapeutics and Kineta.
The action follows the completion on 30 June 2025 of the two-step merger in which Kineta became a wholly-owned subsidiary of TuHURA Biosciences, Inc. (First Merger) and was subsequently merged into Hura Merger Sub II, LLC, which now operates as 鈥淜ineta, LLC.鈥� Because the merger terminated the underlying employee equity plans, the offerings contemplated by the affected S-8 statements have ended. In accordance with undertakings in each Form S-8, Kineta is formally removing from registration the remaining unissued shares.
Key details:
- 9 Form S-8 registration statements affected (Reg. Nos. 333-210521, 218544, 223664, 230155, 237181, 252691, 252692, 256853, 268969).
- Plans covered include Proteostasis 2008 & 2016 plans, ESPP, Yumanity 2018 & 2021 plans, and Kineta 2008, 2010, 2020 & 2022 plans.
- All remaining shares, including previously assumed awards (e.g., 908,205 option/RSU shares and 2,315,860 reserved shares under the Kineta 2022 EIP), are now deregistered.
- James A. Bianco, M.D., signed the amendment in Tampa, Florida on behalf of Kineta, LLC.
The filing is procedural, has no impact on current share-count reporting at TuHURA, and simply eliminates potential future dilution from the unsold shares.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
What is the core business of ADC Therapeutics SA?
Which therapeutic areas does ADC Therapeutics target?
How does ADC Therapeutics generate revenue?
What distinguishes ADC Therapeutics' approach to cancer treatment?
Where is ADC Therapeutics headquartered and what is its global presence?
What role do clinical trials play in ADC Therapeutics' strategy?
How does ADC Therapeutics enhance its industry expertise?
How does ADC Therapeutics ensure the quality and safety of its therapies?
